Hibiki Udagawa

Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

Bob T. Li, Egbert F. Smit, Yasushi Goto et al. · New England Journal of Medicine · 2021 · 886 citations · Full text

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada et al. · Nature Immunology · 2020 · 785 citations

Cancer Immunosurveillance, Autoimmune Disease, T-regulatory Cell +12

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan et al. · Nature · 2021 · 416 citations · Full text

Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung

Tomohiro Miyoshi, Shigeki Umemura, Yuki Matsumura et al. · Clinical Cancer Research · 2016 · 189 citations · Full text

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

Egbert F. Smit, Kazuhiko Nakagawa, Misako Nagasaka et al. · Journal of Clinical Oncology · 2020 · 118 citations

Immunology, Pathology, Data Cutoff +20